Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,Yu Chen ,Zhejiang ,Suzhou ,Jiangsu ,Fujian ,Rhui Zhou ,Guangdong ,Australia ,United States ,Innovent Biologics ,Tingbo Liang ,Sanofi Incyte ,Eli Lilly ,Prnewswire Innovent Biologics Inc ,Zhejiang University ,School Of Medicine ,European Society For Medical Oncology ,Md Anderson Cancer Center ,Linkedin ,European Society ,Medical Oncology ,Virtual Plenary ,Senior Vice President ,Colorectal Cancer ,Fujian Cancer Hospital ,First Affiliated Hospital ,